EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions

Saba Hajibandeh, Yen-An Tao, Ming-Hui Hsieh, Hsuan-Hui Grace Liu, Yi-Fen Cheng, Kuan-Hsun Lee, Shin-Yuh Hsieh, Chi-Hua Lu

Journal of the American Pharmacists Association · 2026-07 · 66 (4) · 103117

DOI: 10.1016/j.japh.2026.103117 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Pharmacists Association, 2026-07. Verfasst von Saba Hajibandeh und 7 weiteren Autor:innen. Die Arbeit nennt 54 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), particularly semaglutide, have demonstrated substantial efficacy for glycemic control and weight management and are increasingly prescribed across diverse populations. Rapid expansion of indications, formulations, and real-world use has outpaced comprehensive evaluation of long-term safety, tolerability, and adherence, raising important concerns for clinical practice. OBJECTIVES This narrative review aims to synthesize current evidence on the efficacy and safety profile of semaglutide, with a focus on adverse events, treatment persistence, perioperative considerations, and use in special populations, to support clinical decision-making and pharmacist-led patient care. METHODS A review of clinical trials, observational studies, pharmacovigilance reports, regulatory communications, and professional guidelines was conducted. Evidence was drawn from randomized controlled trials, post-marketing safety reports, systematic reviews, and relevant clinical and regulatory documents. RESULTS From 1525 records, 34 studies and reports were included. Clinical trials consistently demonstrated meaningful weight reduction with semaglutide. Evidence regarding acute pancreatitis remains limited, although cases have been reported in clinical trials and postmarketing safety analyses. Evidence regarding suicidal ideation associated with semaglutide is mixed, with some analyses suggesting potential safety signals while others report no increased risk. Recent multi society clinical guidelines have addressed perioperative management of GLP-1 RAs, generally supporting individualized perioperative assessment. Emerging literature also examines semaglutide use in special populations, including patients with Alzheimer disease and individuals following bariatric surgery, although long-term neurologic and post-bariatric safety outcomes remain incompletely characterized. CONCLUSIONS Semaglutide represents an important therapeutic option for chronic weight management. As clinical use expands, continued evaluation of long-term safety, tolerability, and treatment persistence will be important. Pharmacists play a key role in counseling patients, monitoring adverse effects, supporting adherence, and contributing to multidisciplinary obesity care.

Zitieren

APA

Hajibandeh, S., Tao, Y. A., Hsieh, M. H., Liu, H. G., Cheng, Y. F., Lee, K. H., Hsieh, S. Y., & Lu, C. H. (2026). Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions. Journal of the American Pharmacists Association, 66(4), 103117. https://doi.org/10.1016/j.japh.2026.103117

Vancouver

Hajibandeh S, Tao YA, Hsieh MH, Liu HG, Cheng YF, Lee KH, et al. Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions. Journal of the American Pharmacists Association. 2026;66(4):103117. doi:10.1016/j.japh.2026.103117

BibTeX
@article{Hajibandeh2026,
  author = {Hajibandeh, Saba and Tao, Yen-An and Hsieh, Ming-Hui and Liu, Hsuan-Hui Grace and Cheng, Yi-Fen and Lee, Kuan-Hsun and Hsieh, Shin-Yuh and Lu, Chi-Hua},
  title = {Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions},
  journal = {Journal of the American Pharmacists Association},
  year = {2026},
  volume = {66},
  number = {4},
  pages = {103117},
  doi = {10.1016/j.japh.2026.103117}
}
Kostenlos starten →